HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $92
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reaffirmed a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $82 to $92, indicating a positive outlook on the company's stock.
January 17, 2024 | 11:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' stock may see a positive short term impact due to the maintained Buy rating and increased price target from $82 to $92 by HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators for investors, often influencing stock prices. The increase in price target by HC Wainwright & Co. suggests a strong conviction in Apellis Pharmaceuticals' potential, likely leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100